[go: up one dir, main page]

MX2019000175A - Canales iónicos activados por ligando modificados y métodos de uso. - Google Patents

Canales iónicos activados por ligando modificados y métodos de uso.

Info

Publication number
MX2019000175A
MX2019000175A MX2019000175A MX2019000175A MX2019000175A MX 2019000175 A MX2019000175 A MX 2019000175A MX 2019000175 A MX2019000175 A MX 2019000175A MX 2019000175 A MX2019000175 A MX 2019000175A MX 2019000175 A MX2019000175 A MX 2019000175A
Authority
MX
Mexico
Prior art keywords
methods
modified
ion channels
lgic
gated ion
Prior art date
Application number
MX2019000175A
Other languages
English (en)
Inventor
Lee Peter
Sternson Scott
Magnus Christopher
Original Assignee
Hughes Howard Med Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hughes Howard Med Inst filed Critical Hughes Howard Med Inst
Publication of MX2019000175A publication Critical patent/MX2019000175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)

Abstract

Este documento se refiere a materiales y métodos para controlar la actividad de los canales iónicos activados por ligando (LGIC). Por ejemplo, se proveen LGIC modificados que incluyen por lo menos una subunidad de LGIC que tiene un dominio de unión de ligando (LBD) modificado y/o un dominio de poro iónico (IPD) modificado. También se proveen ligandos de LGIC exógenos que se pueden unir y activar al LGIC modificado, y también métodos de modulación del transporte iónico a través de la membrana de una célula de un mamífero, métodos de modulación de la excitabilidad de una célula de un mamífero, y métodos de tratamiento de un mamífero que tiene una canalopatía.
MX2019000175A 2016-07-07 2017-07-07 Canales iónicos activados por ligando modificados y métodos de uso. MX2019000175A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359534P 2016-07-07 2016-07-07
US201762486779P 2017-04-18 2017-04-18
PCT/US2017/041147 WO2018009832A1 (en) 2016-07-07 2017-07-07 Modified ligand-gated ion channels and methods of use

Publications (1)

Publication Number Publication Date
MX2019000175A true MX2019000175A (es) 2020-01-20

Family

ID=60892565

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000175A MX2019000175A (es) 2016-07-07 2017-07-07 Canales iónicos activados por ligando modificados y métodos de uso.
MX2022013766A MX2022013766A (es) 2016-07-07 2019-01-07 Canales ionicos activados por ligando modificados y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013766A MX2022013766A (es) 2016-07-07 2019-01-07 Canales ionicos activados por ligando modificados y metodos de uso.

Country Status (14)

Country Link
US (5) US11084853B2 (es)
EP (1) EP3481858A4 (es)
JP (3) JP7755922B2 (es)
KR (2) KR102874080B1 (es)
CN (2) CN110023331B (es)
AU (2) AU2017293925C1 (es)
BR (1) BR112019000182A2 (es)
CA (1) CA3030147A1 (es)
IL (3) IL304040B2 (es)
MX (2) MX2019000175A (es)
NZ (1) NZ749744A (es)
SG (1) SG11201900085TA (es)
WO (1) WO2018009832A1 (es)
ZA (2) ZA201900456B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3030147A1 (en) 2016-07-07 2018-01-11 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
US11713470B2 (en) * 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
JP2021502101A (ja) * 2017-11-10 2021-01-28 ハワード ヒューズ メディカル インスティチュート 修飾されたリガンド依存性イオンチャネルおよび使用の方法
SG11202004488TA (en) 2017-11-27 2020-06-29 Coda Biotherapeutics Inc Compositions and methods for neurological diseases
KR102489109B1 (ko) * 2020-06-02 2023-01-16 부산대학교 산학협력단 아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물
US20240317834A1 (en) * 2020-08-21 2024-09-26 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
WO2022255915A1 (en) * 2021-06-01 2022-12-08 Agneta Nordberg Pet radiotracers
EP4473002A2 (en) * 2022-01-31 2024-12-11 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
EP4479421A1 (en) * 2022-02-18 2024-12-25 Trames Bio, Inc. Ligand gated ion channels and methods of use
EP4514831A1 (en) * 2022-04-27 2025-03-05 Howard Hughes Medical Institute Chemogenetic receptors and methods of making and using
WO2024227060A1 (en) * 2023-04-28 2024-10-31 Kriya Therapeutics, Inc. Chimeric modified ion channels and uses thereof for treatment of trigeminal nerve disorders
CN116731008B (zh) * 2023-06-15 2025-10-24 西北大学 标记肺癌靶点烟碱型乙酰胆碱受体的免洗型荧光探针及制备方法
WO2025015092A1 (en) 2023-07-10 2025-01-16 Kriya Therapeutics, Inc. Novel cam-kinase promoter and uses thereof for treating nervous system disorders
GB202401492D0 (en) * 2024-02-05 2024-03-20 Ucl Business Ltd Chloride channels and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321107C (zh) 2001-04-20 2007-06-13 辉瑞产品公司 1,3－取代的茚类和芳基稠合的氮杂多环化合物的制备方法
US20040204862A1 (en) * 2003-04-11 2004-10-14 Wainer Irving W. Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
CN101044140A (zh) * 2004-04-22 2007-09-26 记忆药物公司 吲哚、1h－吲唑、1,2－苯并异噁唑和1,2－苯并异噻唑以及它们的制备和用途
CA2567977A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
CA2644458A1 (en) 2006-03-01 2007-09-07 Galderma Research & Development Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
US20090123945A1 (en) * 2007-06-27 2009-05-14 Abbott Laboratories Cholinergic/serotoninergic receptor and uses thereof
US9134307B2 (en) 2007-07-11 2015-09-15 X-Body, Inc. Method for determining ion channel modulating properties of a test reagent
JP5775819B2 (ja) 2008-10-09 2015-09-09 ハワード ヒューズ メディカル インスティチュート 新規なキメラリガンド開口型イオンチャネルおよびその使用方法
AR077611A1 (es) * 2009-07-31 2011-09-07 Nabi Biopharmaceuticals Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
WO2015069752A1 (en) * 2013-11-05 2015-05-14 The Regents Of The University Of California Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
CA3030147A1 (en) 2016-07-07 2018-01-11 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
JP2021502101A (ja) * 2017-11-10 2021-01-28 ハワード ヒューズ メディカル インスティチュート 修飾されたリガンド依存性イオンチャネルおよび使用の方法

Also Published As

Publication number Publication date
US11084853B2 (en) 2021-08-10
US20210403522A1 (en) 2021-12-30
JP2019530468A (ja) 2019-10-24
JP7755922B2 (ja) 2025-10-17
IL304040B1 (en) 2024-05-01
US20200377566A1 (en) 2020-12-03
WO2018009832A1 (en) 2018-01-11
CA3030147A1 (en) 2018-01-11
US20220041671A1 (en) 2022-02-10
KR20190044617A (ko) 2019-04-30
MX2022013766A (es) 2022-11-30
CN110023331A (zh) 2019-07-16
ZA201900456B (en) 2021-06-30
US10981962B2 (en) 2021-04-20
BR112019000182A2 (pt) 2019-04-16
AU2017293925A1 (en) 2019-01-24
IL264098B1 (en) 2023-08-01
IL304040B2 (en) 2024-09-01
IL304040A (en) 2023-08-01
CN110023331B (zh) 2024-09-17
KR102874080B1 (ko) 2025-10-23
SG11201900085TA (en) 2019-02-27
CN119120484A (zh) 2024-12-13
KR20230145505A (ko) 2023-10-17
JP2025069252A (ja) 2025-04-30
IL311984A (en) 2024-06-01
US20190375807A1 (en) 2019-12-12
IL264098B2 (en) 2023-12-01
NZ749744A (en) 2025-11-28
AU2024203888A1 (en) 2024-06-27
AU2022202948B2 (en) 2024-03-07
US20180009862A1 (en) 2018-01-11
ZA202101867B (en) 2022-08-31
US11124554B2 (en) 2021-09-21
EP3481858A4 (en) 2020-06-24
AU2022202948C1 (en) 2024-09-26
AU2017293925C1 (en) 2025-02-27
AU2017293925B2 (en) 2022-02-03
JP7538902B2 (ja) 2024-08-22
IL264098A (en) 2019-01-31
EP3481858A1 (en) 2019-05-15
AU2022202948A1 (en) 2022-06-16
JP2023040251A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
MX2022013766A (es) Canales ionicos activados por ligando modificados y metodos de uso.
CO2019000931A2 (es) Polipéptidos modificados y usos de los mismos
MX391068B (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina.
CL2017000416A1 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
MX2022002959A (es) Anticuerpos anti-tigit y metodos de uso.
MX392031B (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
MX2018004988A (es) Moleculas de union que inhibe el crecimiento de cancer.
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
MX2016016369A (es) Tratamiento de linfomas.
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
BR112017018941A8 (pt) Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
EP3590233A4 (en) ARCHITECTURE FOR INTEGRATING A SERVICE, DOMAIN AND NETWORK MANAGEMENT SUBSYSTEMS
EP3508456A4 (en) COMPOSITE FILTER CARTRIDGE, COMPOSITE FILTER CARTRIDGE ARRANGEMENT FOR WATER TREATMENT AND WATER TREATMENT
DK3223845T3 (da) Heterodimere antistoffer, der binder cd3 og cd20
AR104309A1 (es) Construcciones de anticuerpos biespecíficos para cdh3 y cd3
MX383370B (es) Afeitadora de dos filos.
MX2021008216A (es) Anticuerpos anti-tigit.
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
MX375340B (es) Un material de lamina polimerica mejorada para su uso en la fabricacion de documentos de seguridad polimericos tales como billetes de banco.
EP3400998A4 (en) COMPOSED FILTER CARTRIDGE
CR20170518A (es) Neutralización del virus chikungunya mediada por anticuerpos.
CL2018001799A1 (es) Elementos estructurados y metodos de uso
TR201902604T4 (tr) Fi̇berglas kompozi̇ti̇, bunun cam fi̇beri̇ ve bunun kompozi̇t materyali̇.
AR110079A1 (es) Factor viii direccionado a los glóbulos rojos y método para su uso